153 related articles for article (PubMed ID: 38745890)
1. Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.
Pergialiotis V; Vogiatzi Vokotopoulou L; Vlachos DE; Liontos M; Kontomanolis E; Thomakos N
Eur J Obstet Gynecol Reprod Biol X; 2024 Jun; 22():100312. PubMed ID: 38745890
[TBL] [Abstract][Full Text] [Related]
2. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
3. Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis.
Ye Q; Cheng J; Ye M; Liu D; Zhang Y
J Gynecol Oncol; 2019 Jan; 30(1):e5. PubMed ID: 30479089
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
7. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
8. Is there a correlation of positive peritoneal washing cytology during interval debulking surgery on the survival outcomes of ovarian cancer patients? A systematic review and meta-analysis of the literature.
Douligeris A; Pergialiotis V; Fasoulakis Z; Rodolakis A; Haidopoulos D
J Gynecol Obstet Hum Reprod; 2022 Jan; 51(1):102256. PubMed ID: 34678477
[TBL] [Abstract][Full Text] [Related]
9. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment thrombocytosis predicts prognosis of endometrial cancer: A meta-analysis of 11 studies.
Ye Q; Wu Z; Xia T; Liu D; Yang Y; Tang H
Exp Ther Med; 2020 Jan; 19(1):359-366. PubMed ID: 31853312
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
16. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
Cozzi GD; Samuel JM; Fromal JT; Keene S; Crispens MA; Khabele D; Beeghly-Fadiel A
BMC Cancer; 2016 Aug; 16():612. PubMed ID: 27502272
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
18. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
19. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
20. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]